Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Champions Oncology, Inc.NASDAQ: CSBR

EBITDA · Q3 FY2026 · quarter ended Jan 2026

EBITDA declines year over year

Q3 FY2026 EBITDA of $104K fell 97.9% year over year, ahead of the -111.2% change in trailing-twelve-month EBITDA. Sequentially, it fell 83.0% from the prior quarter. Over 3 fiscal years it compounded at +41.5% a year.

Context

  • EBITDA amounted to 11.0% of revenue in FY2025, up 0.2 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of $3.48M (-44.5%) for the fiscal year ending Apr 2026, a slowdown from the +215.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJan 2026
$104K-83.0% QoQ
Last fiscal yearApr 2025
$6.27M+215.2% YoY
LTMJan 2026
-$948K-111.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.9%+76.2%+174.1 pp
1 year+215.2%-44.5%-259.7 pp
3-year CAGR+41.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
6.27M USD
Year-over-year change
+215.2%
4-year CAGR
+41.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -111.2% is the 9th highest of 10, against a peer median of +4.6%.
  • EBITDA amounts to 1.6% of revenue for CSBR, versus a peer median of 4623.1%.
CSBR Competitors
EBITDA for CSBR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$78.84M USD+1391.3%——
CSBRChampions Oncology, Inc.LTM Jan 2026-$948K USD-111.2%+41.5%1.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$5.48M USD+4.6%—23.7%
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.08M USD+36.5%——
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M USD+30.8%—4623.1%
IMAImageneBio IncLTM Mar 2026-$51.64M USD-7.8%——
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M USD-270.2%—85279.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$84.44M USD-35.4%——
STROSutro Biopharma, Inc.LTM Mar 2026-$106.12M USD+42.0%—106.5%
Peer median (excluding CSBR) —+4.6%—4623.1%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.